SCHEMBL25955199

SCHEMBL25955199

c1ccc(-c2cccc(-c3cccc(-c4nc(-c5ccc6c(c5)oc5ccccc56)cc(-c5ccc6oc7ccccc7c6c5)n4)c3)c2)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLA2G2A P14555 4/20 0.45
PLA2G4A P47712 4/20 0.45
PLA2G10 O15496 1/20 0.45
MEN1 O00255 7/20 0.43
KMT2A Q03164 7/20 0.43
MAPT P10636 6/20 0.43
ALDH1A1 P00352 5/20 0.43
HPGD P15428 5/20 0.43
KDM4E B2RXH2 4/20 0.43
LMNA P02545 2/20 0.43
HCRTR1 O43613 1/20 0.42
MMP12 P39900 1/20 0.41
MMP13 P45452 1/20 0.41
GLA P06280 1/20 0.40
CASP3 P42574 1/20 0.40
SENP7 Q9BQF6 1/20 0.40
SENP6 Q9GZR1 1/20 0.40
AHR P35869 2/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20977644 0.96 MEN1 (0.46) PLA2G2APLA2G4APLA2G10MEN1KMT2A
SCHEMBL20977650 0.96 MEN1 (0.46) PLA2G2APLA2G4APLA2G10MEN1KMT2A
SCHEMBL20977645 0.96 MEN1 (0.46) PLA2G2APLA2G4APLA2G10MEN1KMT2A
SCHEMBL20977652 0.96 MEN1 (0.46) PLA2G2APLA2G4APLA2G10MEN1KMT2A
SCHEMBL20977653 0.96 MEN1 (0.46) PLA2G2APLA2G4APLA2G10MEN1KMT2A
SCHEMBL20977654 0.96 MEN1 (0.46) PLA2G2APLA2G4APLA2G10MEN1KMT2A
SCHEMBL17899243 0.95 MEN1 (0.43) PLA2G2APLA2G4APLA2G10MEN1KMT2A
SCHEMBL19860951 0.95 PLA2G2A (0.43) PLA2G2APLA2G4APLA2G10MEN1KMT2A
SCHEMBL24217052 0.95 MEN1 (0.47) PLA2G2APLA2G4APLA2G10MEN1KMT2A
SCHEMBL21028969 0.94 MEN1 (0.46) PLA2G2APLA2G4APLA2G10MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230312538-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME LT MATERIALS CO., LTD. (KR) 2023-10-05 US disclosed
US-20230312538-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME LT MATERIALS CO., LTD. (KR) 2023-10-05 US disclosed
EP-4212526-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME LT Materials Co., Ltd. (KR) 2023-07-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230312538-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME CRY1, CYP1A1, CYP1B1 PLA2G2A 3794/4885PLA2G4A 4035/4885PLA2G10 4291/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.